ICER says Luxturna is not cost-effective

In an evidence report published Friday, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective.

The institute said while clinical evidence on Luxturna provides high certainty of at least a small net health benefit for patients with vision loss associated with biallelic retinal pigment epithelium-specific protein 65kDa (RPE65)-mediated retinal disease, uncertainty remains about the long-term effects and durability of the response to treatment. It noted that Luxturna is the only therapy available for the indication...